Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: A cohort study

European Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2013, Pages 279-287

  Wändell, Per ^a   Carlsson, Axel C ^a,b   Sundquist, Kristina ^c,d   Johansson, Sven Erik ^c   Sundquist, Jan ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombotic drugs; Follow up; Gender; Pharmacotherapy; Statins; Thiazides

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGITALIS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SOTALOL; THIAZIDE DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOMYOPATHY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG CLASSIFICATION; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; POPULATION RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SWEDEN; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; COHORT STUDIES; FEMALE; HEMATOLOGIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SWEDEN;

EID: 84873710133     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1395-2     Document Type: Article

References (39)

1. Bajpai A, Savelieva I, Camm AJ (2008) Treatment of atrial fibrillation. Br Med Bull 88(1):75-94. doi: 10.1093/bmb/ldn046
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155(5):469-473
3. Wandell PE (2001) A survey of subjects with present or previous atrial fibrillation in a Swedish community. Scand J Prim Health Care 19(1):20-24 (Pubitemid 32230098)
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A):2N-9N (Pubitemid 28507114)
5. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103(19):2365-2370 (Pubitemid 32448801)
6. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10):946-952 (Pubitemid 28446646)
7. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD (2010) Gender in atrial fibrillation: ten years later. Gend Med 7(3):206-217. doi: 10.1016/j.genm.2010.06.001
8. Bachmann JM, Majmudar M, Tompkins C, Blumenthal RS, Marine JE (2008) Lipid-altering therapy and atrial fibrillation. Cardiol Rev 16(4):197-204. doi: 10.1097/CRD.0b013e318177271d
9. Carlsson AC, Wandell P, Sundquist K, Johansson SE, Sundquist J (2012) Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol. doi: 10.1007/s00228-012-1322-6
10. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J (2012) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 5:CD005049. doi: 10.1002/14651858. CD005049.pub3
11. Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 10(2):155-164 (Pubitemid 38858077)
12. Sundquist K, Li X (2006) Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. J Intern Med 259(4):418-427. doi: 10.1111/j.1365-2796.2006.01630.x (Pubitemid 43384233)
13. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK (2007) Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 25(6):1311-1317 (Pubitemid 46918812)
14. Wandell PE, Carlsson AC, Sundquist K, Johansson SE, Sundquist J (2011) Total mortality among levothyroxine-treated women with atrial fibrillation in Swedish primary health care. Int J Cardiol 152(1):147-148. doi: 10.1016/j.ijcard.2011.07.066
15. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N (2010) Survival after stroke - the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 141(1):18-23. doi: 10.1016/j.ijcard.2008.11.122
16. Seiler J, Stevenson WG (2010) Atrial fibrillation in congestive heart failure. Cardiol Rev 18(1):38-50. doi: 10.1097/CRD.0b013e3181c21cff
17. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M (2006) Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 27(16):1954-1964. doi: 10.1093/eurheartj/ehl146 (Pubitemid 44297370)
18. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8(9):651-745 (Pubitemid 44472247)
19. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278. doi: 10.1016/S0140-6736(05)67394-1 (Pubitemid 41416582)
20. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D (2010) Cholesterol and cardiac arrhythmias. Expert Rev Cardiovasc Ther 8(7):965-979. doi: 10.1586/erc.10.79
21. Wandell PE (2001) Five-year mortality in men and women with atrial fibrillation. Scand J Prim Health Care 19(2):112-116 (Pubitemid 32601774)
22. Wandell PE, Gafvels C (2002) Metabolic control and quality of data in medical records for subjects with type 2 diabetes in Swedish primary care: improvement between 1995 and 2001. Scand J Prim Health Care 20(4):230-235 (Pubitemid 36109409)
23. Wandell PE, Gafvels C (2002) Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001: change over time. Eur J Clin Pharmacol 58(8):547-553. doi: 10.1007/s00228-002-0510-1 (Pubitemid 35435507)
24. Aguilar MI, Hart R, Pearce LA (2007) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev (3):CD006186 doi: 10.1002/14651858.CD006186.pub2 (Pubitemid 351805586)
25. Lane DA, Lip GY (2010) Atrial fibrillation and mortality: the impact of antithrombotic therapy. Eur Heart J 31(17):2075-2076. doi: 10.1093/eurheartj/ ehp486
26. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857-867 (Pubitemid 351650486)
27. Lip GY, Lane DA (2010) Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123(9):785-789. doi: 10.1016/j.amjmed.2010.01.031
28. Grines C, Cho L (2008) Atherothrombotic disease and the role of antiplatelet therapy in women. J Womens Health (Larchmt) 17(1):35-46. doi: 10.1089/jwh.2006.0305 (Pubitemid 351216966)
29. Yerman T, Gan WQ, Sin DD (2007) The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med 5:29. doi: 10.1186/1741-7015-5-29 (Pubitemid 350269071)
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981-2997
31. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R (2006) Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113(18):2201-2210. doi: 10.1161/CIRCULATIONAHA.105.544031
32. Jimenez-Navarro MF, Ramirez-Marrero MA, Anguita-Sanchez M, Castillo JC (2010) Influence of gender on long-term prognosis of patients with chronic heart failure seen in heart failure clinics. Clin Cardiol 33(3):E13-E18. doi: 10.1002/clc.20476
33. Gheorghiade M, Harinstein ME, Filippatos GS (2009) Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care 11(2):83-87. doi: 10.1080/17482940902883246
34. Schrier RW, Masoumi A, Elhassan E (2010) Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 5(6):1132-1140. doi: 10.2215/CJN.01410210
35. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB (2004) Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94(7):889-894. doi: 10.1016/j.amjcard.2004.06.023 (Pubitemid 39359174)
36. Carlsson AC, Theobald H, Hellenius ML, Wandell PE (2009) Cardiovascular and total mortality in men and women with different blood pressure levels - a 26-year follow-up. Blood Press 18(3):105-110. doi: 10.1080/08037050903013881
37. Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J (2011) Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes Metab Res Rev 27(3):244-254. doi: 10.1002/dmrr.1161
38. de Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Borsboom GJ, Mackenbach JP (2005) The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study. BMC Health Serv Res 5(1):10. doi: 10.1186/1472-6963-5-10 (Pubitemid 40300816)
39. Grobbee DE, Hoes AW (1997) Confounding and indication for treatment in evaluation of drug treatment for hypertension. Br Med J 315(7116):1151-1154 (Pubitemid 27470317)